Fremanezumab Compassionate Use Program for Pediatric Patients With Migraine
- Study Title
- Fremanezumab (TEV-48125) Compassionate Use Program for Pediatric Patients (6 to 17 Years) With Chronic or Episodic Migraine
- Teva Identifier
- TV48125-CNS-80005
- ClinicalTrials.gov Identifier
- NCT03539393
- Study Status
- Available
- Trial Condition(s)
- Migraine
- Interventions
- Drug: Fremanezumab
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child
- Age Range
- 6 Years to 17 years
- Trial Duration
- N/A
- Phase
- N/A
